Pharmaco-dynamic influence under ascites or laparotomy on intraperitoneal sequential MTX/5-FU therapy

Maruyama, M.; Irie, T.; Yoshida, T.; Nagahama, T.; Sugano, N.; Ebuchi, M.

Gan to Kagaku Ryoho. Cancer and ChemoTherapy 25(9): 1439-1441

1998


ISSN/ISBN: 0385-0684
PMID: 9703848
Document Number: 491563
We studied pharmaco-dynamic changes of intraperitoneal sequential MTX (30 mg)/5-FU (750 mg) therapy in gastric cancer patients with malignant ascites and those who had undergone a gastrectomy. The serum and ascites levels of MTX in patients with malignant ascites decreased much slower than in patients without ascites. In patients with ascites, the serum MTX concentration peaked 8 hours later and then gradually decreased. The ascites MTX level decreased as low as 1/10 2 days after the intraperitoneal administration. The serum and ascites 5-FU levels revealed a minor prolongation of 5-FU concentration in patients with ascites. Gastrectomy did not affect the pharmaco-dynamics of MTX in post-operative patients with sequential intraperitoneal administration of MTX/5-FU on 1, 8 and 15 POD.

Document emailed within 1 workday
Secure & encrypted payments